Event-free survival of patients with high-risk neuroblastoma treated with an N6-like induction treatment.

[1]  K. Ness,et al.  Long‐term complications in survivors of advanced stage neuroblastoma , 2005, Pediatric blood & cancer.

[2]  T. Klingebiel,et al.  1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. , 1997, European journal of cancer.

[3]  K K Matthay,et al.  Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .

[4]  W. Gerald,et al.  Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Cheung,et al.  Camptothecin Analogs (Irinotecan or Topotecan) plus High-Dose Cyclophosphamide as Preparative Regimens for Antibody-Based Immunotherapy in Resistant Neuroblastoma , 2004, Clinical Cancer Research.

[6]  G. Heller,et al.  Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  N. Cheung,et al.  Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Bergeron,et al.  Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Gerald,et al.  N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. , 2001, Medical and pediatric oncology.

[10]  N. Cheung,et al.  Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.